Prophylaxis of hepatitis B reactivation using lamivudine in a patient receiving rituximab

This publication has 9 references indexed in Scilit:

• Acute Hepatitis B in a Patient with Antibodies to Hepatitis B Surface Antigen Who Was Receiving Rituximab
  New England Journal of Medicine, 2001
• Rituximab (anti-CD20 monoclonal antibody) as single first-line therapy for patients with follicular lymphoma with a low tumor burden: clinical and molecular evaluation
  Blood, 2001
• Frequency of hepatitis B virus reactivation in cancer patients undergoing cytotoxic chemotherapy: A prospective study of 626 patients with identification of risk factors
  Journal of Medical Virology, 2000
• Pure red cell aplasia due to parvovirus B19 in a patient treated with rituximab
  Blood, 2000
• Lamivudine allows completion of chemotherapy in lymphoma patients with hepatitis B reactivation
  British Journal of Haematology, 2000
• Prevention of hepatitis B flare-up during chemotherapy using lamivudine: case report and review of the literature
  Annals of Hematology, 1999
• Treatment of Patients With Low-Grade B-Cell Lymphoma With the Combination of Chimeric Anti-CD20 Monoclonal Antibody and CHOP Chemotherapy
  Journal of Clinical Oncology, 1999
• IDEC-C2B8 (Rituximab) Anti-CD20 Monoclonal Antibody Therapy in Patients With Relapsed Low-Grade Non-Hodgkin's Lymphoma
  Blood, 1997
• Reactivation of precore mutant hepatitis B virus leading to fulminant hepatic failure following cytotoxic treatment
  Digestive Diseases and Sciences, 1992